Advanced Medical Institute (AMI)
Advanced Medical Institute (AMI), through its wholly owned subsidiary, Advanced Medical Institute Pty Limited, headquartered in Sydney, Australia, is a leading provider of treatment programs for erectile dysfunction and premature ejaculation. The Company operates 22 treatment clinics in Australia, has more than 130 employees, including 25 medical personnel, and since its inception has provided treatment to more than 250,000 patients. AMI Australia and its predecessor company began treating ED and PE patients successfully 5 years prior to the launch of Viagra, in 1998, in Australia.
Advanced Medical Institute (AMI) are the pioneers of nasal spray technology for sexual health in Australia. They primarily specialise in providing treatments to sufferers of erectile dysfunction and premature ejaculation and have clinic locations all throughout Australia and New Zealand. AMI Australia is a 100% subsidiary of a publicly listed company (AMI Australia) in the USA (Nasdaq). AMI Australia has over 280 personnel, including 48 medical professionals who deliver a high level of back-up service and support to patients, including a 24-hour national patient support line.
Advanced Medical Institute (AMI) understands men's health needs and over the past 15 years AMI has been providing the opportunity for individuals to improve their sexual health by making access simple and easy. Since 1993 AMI has treated over 300,000 individuals, including men who have sustained a spinal cord injury. Through a wide range of treatment options AMI Australia helps restore the quality of life for men of all ages with different medical conditions (including Parkinson disease, Multiple Sclerosis, spinal cord injuries, tetra and quadriplegic) that is otherwise lost to these patients and their partners and discretely delivers these products directly to their doors.
Advanced Medical Institute (AMI), a leading provider of treatment for Erectile Dysfunction and Premature Ejaculation in Australasia, is pleased to announce Advanced Medical Institute (AMI) has exercised its rights to extend its option period to exclusively license the intellectual property of AMI wholly owned subsidiary, Worldwide PE Patent Holdco Pty Limited, for use in the United Kingdom. AMI confirms that it has received an additional non-refundable extension fee of $50,000 and that it has agreed to extend the option period by 4 months. Advanced Medical Institute (AMI) also confirms that it has been advised by (AMI) UK that AMI UK is in advanced discussions with a funding partner and that it currently anticipates exercising its option in late October or early November.
AMI nasal Spray developed and patented by the Advanced Medical Institute (AMI) of Australia. AMI are also based in New Zealand and now Europe under amieurope.co.uk. The nasal sprays developed by this company have been under a lot of scrutiny lately and this adds to all the controversy the company as a whole has attracted since its inception in Australia. Advanced Medical Institute (AMI) will now conduct business in the UK through its wholly owned subsidiary, AMI Clinic Limited (AVMD UK).
